DEXCOM INC $DXCM
Hunterbrook Media • Published September 2025 • Fatal Flaws: G7 Users Hospitalized and Dead
CORE INVESTMENT THESIS
Dexcom is a failing medical device company whose flagship G7 continuous glucose monitor has caused hospitalizations and deaths.
The company cut corners, compromised safety protocols, and used unauthorized materials that performed worse by "every accuracy metric." Hunterbrook concludes this is a SHORT POSITION with significant downside risk.
COMPANY OVERVIEW
CRITICAL RED FLAGS
FDA cited Dexcom for "adulterated" devices using unauthorized materials that performed worse by "every accuracy metric"
22% more FDA accuracy complaints than expected based on market share, while Abbott logs 68% fewer
Days Sales Outstanding hit record 106 days, suggesting aggressive revenue recognition and channel stuffing
CEO, CCO, VP Global Operations, and Head of Engineering all left within a year. No insider purchases since 2020
G7 Safety Crisis Timeline
KEY PLAYERS
COMPETITIVE THREATS
Better accuracy than G7's 8.2% MARD. Abbott claims it will "100%" take market share from Dexcom
Abbott developing dual glucose/ketone sensors - major upgrade Dexcom hasn't committed to matching
Proposed Medicare competitive bidding could significantly reduce CGM reimbursement rates
Ozempic and similar drugs may slow Type 2 diabetes progression, reducing addressable market
FDA Complaint Surge After Material Change
PATIENT IMPACT STORIES
Diana Bates Knight
"G7 misread her daughter's glucose level by hundreds of points, sending the child to the emergency room with a life-threatening complication."
Mother of 6-year-old Type 1 diabeticBob Hawkinson
"Passed out behind the wheel when his G7 failed to alert him to dangerously low blood sugar levels."
Lifelong diabetic since infancyCourtney Duffy
"Found unresponsive by roommate, woke up in ambulance when G7 failed to connect to automated insulin pump."
Young adult with Type 1 diabetesKelli Danielson
"Found unresponsive by husband after G7 completely failed. Blood sugar fell beneath detectable limits. 'What if I lived alone? I really could have died!'"
Pharmacist and diabetic patientAccounting Manipulation Timeline
Hunterbrook Media's Verdict
According to Hunterbrook Media, Dexcom ($DXCM) is a failing medical device company whose rush to compete with Abbott led to compromised safety protocols and a defective flagship product. The G7 continuous glucose monitor has been linked to hospitalizations and deaths, with the FDA citing the company for using unauthorized materials that performed worse by "every accuracy metric." Hunterbrook concludes this represents a significant short opportunity with substantial downside risk.
DISCLAIMER: Based on Hunterbrook Media's reporting, Hunterbrook Capital is short $DXCM and hedging with derivatives. Claims are being investigated by Wisner Baum LLP. Petition filed with FDA. This dashboard is for informational purposes only and does not constitute investment advice.